Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154
Presenter:
Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine
Session:
Pharmaceutical Pipeline (Oral Presentation)
Date:
Tuesday, May 26, 2026
Time:
3:20 PM ET
Location:
Loews Miami Beach Hotel, Miami, FL
The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).
Login to comment